July 2019
Volume 60, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2019
Incidence and Features of Geographic Atrophy in Fellow Eyes in the Comparison of Age-related Macular Degeneration Treatment Trials (CATT)
Author Affiliations & Notes
  • Delu Song
    Research & Development, Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Gui-Shuang Ying
    Research & Development, Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Juan E Grunwald
    Research & Development, Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Ebenezer Daniel
    Research & Development, Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Maureen G Maguire
    Research & Development, Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Yafeng Li
    Research & Development, Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Daniel F Martin
    Cole Eye Institute, Cleveland, Ohio, United States
  • Footnotes
    Commercial Relationships   Delu Song, None; Gui-Shuang Ying, None; Juan Grunwald, None; Ebenezer Daniel, None; Maureen Maguire, None; Yafeng Li, None; Daniel Martin, None
  • Footnotes
    Support  U10 EY017823, U10 EY017825, U10 EY017826, and U10 EY017828
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 1144. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Delu Song, Gui-Shuang Ying, Juan E Grunwald, Ebenezer Daniel, Maureen G Maguire, Yafeng Li, Daniel F Martin; Incidence and Features of Geographic Atrophy in Fellow Eyes in the Comparison of Age-related Macular Degeneration Treatment Trials (CATT). Invest. Ophthalmol. Vis. Sci. 2019;60(9):1144.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To describe the incidence and characteristics of geographic atrophy (GA) in fellow eyes of patients with unilateral choroidal neovascularization (CNV) treated with anti-VEGF injections in the Comparison of Age-related Macular Degeneration (AMD) Treatment Trials (CATT).

Methods : Participants with untreated neovascular AMD in their study eye were randomly assigned to ranibizumab or bevacizumab (monthly or PRN). After 2 years of treatment, participants were released from the treatment protocol and recalled for follow up examination at 5 years. Patients at baseline with no GA in either eye and no CNV in the fellow eye were included. Bilateral, stereoscopic color fundus photographs were assessed for GA by two masked graders at baseline, years 1, 2 and 5. Proportional odds logistic regression was used to identify factors associated with the number of eyes developing GA.

Results : Among 599 eligible participants, the cumulative incidence in fellow eyes vs study eyes is 0.05 vs 0.07 by year 1, 0.10 vs 0.13 by year 2, 0.33 vs 0.34 by year 5 (p=0.12). For participants assigned to ranbizumab treatment, GA incidence in the fellow eye was lower than that of study eye (0.05 vs 0.10 by year 1, 0.11 vs 0.16 by year 2, 0.32 vs 0.40 by year 5, p=0.009), while GA incidence in the fellow eye was similar for both drugs used for the study eye (p=0.91) (Figure 1). Among 196 (32.7%) participants with incident GA in either eye during follow-up, GA was bilateral in 76 (38.8%) participants and detected in both eyes at the same visit in 48 (63.2%) participants. In multivariate analysis, female gender (OR=1.69, p=0.009), number of eyes with pseudodrusen (OR=1.60, p<0.0001) and number of T risk alleles in Toll-like receptor 3 (OR=1.42, p=0.03) were associated with higher number of eyes with GA (Table 1).

Conclusions : Among CATT participants without CNV in the fellow eye at baseline, one third of participants developed GA in their fellow eye by 5 years, similar to the GA incidence in the study eye. Among participants with ranibizumab treatment in study eyes, GA incidence was lower in the fellow eye than the study eye. Female gender, pseudodrusen, and risk allele C in Toll-like receptor 3 were risk factors for GA.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×